


Claims:

1. A compound of Formula (I):



wherein


R₁ is a bicyclic ring system which contains 9 to 11 ring members including 1 to 4 hetero atoms, in which said bicyclic ring system may be substituted by 1 to 3 groups selected from the group consisting of C₁-C₆alkyl, substituted C₁-C₆alkyl, C₃-C₇cycloalkyl, halo, hydroxyl, oxo, amide, carboxylic acid, -C(O)R_a, -SO₂R_a, arylalkyl, -(C₁-C₃alkyl)aryloxy, aryl, heteroaryl and C₁-C₄alkoxy,

in which each R_a is independently C₁-C₆alkyl, substituted C₁-C₆alkyl or unsubstituted C₃-C₇cycloalkyl;

each R₂ and R₃ is independently hydrogen, C₁-C₆alkyl, substituted C₁-C₆alkyl, halo, hydroxyl, amide, carboxylic acid or C₁-C₄alkoxy; and
m is 0-2;

or a pharmaceutically acceptable salt thereof.

2. A compound of claim 1, which is represented by Formula (I)(A)



wherein A is a 5- or 6-membered heterocyclic ring, which may contain 0 to 3 double bonds and may be substituted by 1 to 3 groups selected from the group consisting of

C₁-C₆alkyl, substituted C₁-C₆alkyl, C₃-C₇cycloalkyl, halo, hydroxyl, oxo, amide, carboxylic acid, -C(O)R_a, -SO₂R_a, arylalkyl, -(C₁-C₃alkyl)aryloxy, aryl, heteroaryl and C₁-C₄alkoxy,

5 in which each R_a is independently C₁-C₆alkyl, substituted C₁-C₆alkyl or unsubstituted C₃-C₇cycloalkyl;

each R₂ and R₃ is independently hydrogen, C₁-C₆alkyl, substituted C₁-C₆alkyl, halo, hydroxyl, amide, carboxylic acid or C₁-C₄alkoxy;

R₄ is halo or alkoxy;

X is N or CH; and

10 m is 0-2;

n is 0-2;

or a pharmaceutically acceptable salt thereof.

15 3. A compound of claim 2, wherein A is a 5-membered heterocyclic ring, which may contain 0-2 double bonds and may be substituted by 1 to 3 groups selected from the group consisting of C₁-C₆alkyl, substituted C₁-C₆alkyl, C₃-C₇cycloalkyl, halo, hydroxyl, oxo, amide, carboxylic acid, -C(O)R_a, -SO₂R_a, arylalkyl, -(C₁-C₃alkyl)aryloxy, aryl, heteroaryl and C₁-C₄alkoxy,

20 in which each R_a is independently C₁-C₆alkyl, substituted C₁-C₆alkyl or unsubstituted C₃-C₇cycloalkyl;

each R₂ and R₃ is independently hydrogen, C₁-C₆alkyl, substituted C₁-C₆alkyl, halo, hydroxyl, amide, carboxylic acid or C₁-C₄alkoxy;

R₄ is halo or alkoxy;

25 X is N or CH; and

m is 0-2;

n is 0-2;

or a pharmaceutically acceptable salt thereof.

30 4. A compound of claim 2, wherein A is a 6-membered heterocyclic ring, which may contain 0-3 double bonds and may be substituted by 1 to 3 groups selected from the group consisting of C₁-C₆alkyl, substituted C₁-C₆alkyl, C₃-C₇cycloalkyl, halo, hydroxyl, oxo, amide, carboxylic acid, -C(O)R_a, -SO₂R_a, arylalkyl, -(C₁-C₃alkyl)aryloxy, aryl, heteroaryl and C₁-C₄alkoxy,

35

- in which each R_a is independently C_1 - C_6 alkyl, substituted C_1 - C_6 alkyl or unsubstituted C_3 - C_7 cycloalkyl;
each R_2 and R_3 is independently hydrogen, C_1 - C_6 alkyl, substituted C_1 - C_6 alkyl, halo, hydroxyl, amide, carboxylic acid or C_1 - C_4 alkoxy;
5 R_4 is halo or alkoxy;
 X is N or CH; and
 m is 0-2;
 n is 0-2;
or a pharmaceutically acceptable salt thereof.
- 10 5. A compound of any one of claims 2-4,
wherein m is 0;
 n is 0;
 R_3 is hydrogen; and
15 X is N;
or a pharmaceutically acceptable salt thereof.
- 20 6. A compound of any one of claims 2-4,
wherein m is 0;
 n is 0;
 R_3 is hydrogen; and
 X is CH;
or a pharmaceutically acceptable salt thereof.
- 25 7. A compound of claim 1,
wherein m is 0,
 R_3 is hydrogen;
 R_1 is a bicyclic ring system selected from the group consisting of
tetrahydroisoquinoliny, tetrahydroquinoliny, indolyl, dihydroindolyl, indazolyl,
30 dihydroindazolyl, benzothiophenyl, benzodiazolyl, dihydrobenzodiazolyl,
benzimidazolyl, indoliny, benzotriazolyl, pyrrolopyridiny, benzothiazolyl,
benzofuranyl, dihydroquinazoliny, and pyrrolopyrimidinyl;
wherein said bicyclic ring system may be substituted by 1 to 3 groups selected
from the group consisting of C_1 - C_6 alkyl, substituted C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl,

halo, hydroxyl, oxo, amide, carboxylic acid, $-C(O)R_a$, $-SO_2R_a$, arylalkyl, $-(C_1-C_3alkyl)aryloxy$, aryl, heteroaryl and $C_1-C_4alkoxy$,

in which each R_a is independently C_1-C_6alkyl , substituted C_1-C_6alkyl or unsubstituted $C_3-C_7cycloalkyl$;

or a pharmaceutically acceptable salt thereof.

8. A compound of claim 7,

wherein m is 0;

R_3 is hydrogen;

R_1 is a bicyclic ring system selected from the group consisting of tetrahydroisoquinolinyl, tetrahydroquinolinyl, indolyl, dihydroindolyl, indazolyl, dihydroindazolyl, and pyrrolopyridinyl;

wherein said bicyclic ring system may be substituted by 1 to 3 groups selected from the group consisting of C_1-C_6alkyl , substituted C_1-C_6alkyl , $C_3-C_7cycloalkyl$, halo, hydroxyl, oxo, amide, carboxylic acid, $-C(O)R_a$, $-SO_2R_a$, arylalkyl, $-(C_1-C_3alkyl)aryloxy$, aryl, heteroaryl and $C_1-C_4alkoxy$,

in which each R_a is independently C_1-C_6alkyl , substituted C_1-C_6alkyl or unsubstituted $C_3-C_7cycloalkyl$;

or a pharmaceutically acceptable salt thereof.


9. The compound according to any one of claims 1-7.

10. A method of treating obesity comprising administering to a human in need thereof an effective amount of a compound according to any one of the above claims.

11. A pharmaceutical composition comprising a compound according to any one of claims 1-7, and a pharmaceutically acceptable carrier.

CLAIMS

1. A compound of Formula (I):



5

wherein

- R_1 is a bicyclic ring system which contains 9 to 11 ring members including 1 to 4 hetero atoms independently selected from the group consisting of N, O, and S, in which said bicyclic ring system may be substituted by 1 to 3 groups independently selected from the group consisting of C_1 - C_6 alkyl, substituted C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, halo, hydroxyl, oxo, $-\text{C}(\text{O})\text{NR}^c\text{R}^d$, $-\text{COOH}$, $-\text{C}(\text{O})\text{R}_a$, $-\text{SO}_2\text{R}_a$, arylalkyl, $-(\text{C}_1$ - C_3 alkyl)aryloxy, aryl, heteroaryl and C_1 - C_4 alkoxy,

- in which each R_a is independently C_1 - C_6 alkyl, substituted C_1 - C_6 alkyl or unsubstituted C_3 - C_7 cycloalkyl;


- 15 R_3 is hydrogen; and

m is 0;

- wherein any said substituted C_1 - C_6 alkyl is substituted by 1 to 3 groups independently selected from the group consisting of unsubstituted C_3 - C_7 cycloalkyl, methyl, ethyl, propyl, isopropyl, butyl, *t*-butyl, difluoromethyl, trifluoromethyl, halo, $-\text{NR}'\text{R}''$, cyano, hydroxyl, C_1 - C_4 alkoxy, $-\text{COOH}$, $-\text{COO}(\text{methyl})$, $-\text{COO}(\text{ethyl})$, and $-\text{C}(\text{O})\text{NR}^c\text{R}^d$, wherein R' and R'' are each independently selected from the group consisting of hydrogen, unsubstituted C_1 - C_6 alkyl, $-\text{C}(\text{O})\text{R}^b$, and unsubstituted C_3 - C_7 cycloalkyl, wherein R^b is unsubstituted C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, or heterocyclyl;

- and wherein each R^c and R^d are independently hydrogen or C_1 - C_6 alkyl;
- 25 or a pharmaceutically acceptable salt thereof.

2. A compound of Formula (I)(A)



wherein A is a 5- or 6-membered heterocyclic ring, which may contain 1 to 3 double bonds and may be substituted by 1 to 3 groups independently selected from the group consisting of

5 C₁-C₆alkyl, substituted C₁-C₆alkyl, C₃-C₇cycloalkyl, halo, hydroxyl, oxo, -C(O)NR^cR^d, -COOH, -C(O)R_a, -SO₂R_a, arylalkyl, -(C₁-C₃alkyl)aryloxy, aryl, heteroaryl and C₁-C₄alkoxy,

in which each R_a is independently C₁-C₆alkyl, substituted C₁-C₆alkyl or unsubstituted C₃-C₇cycloalkyl;

10 R₃ is hydrogen;

R₄ is halo or alkoxy;

X is N or CH; and

m is 0;

wherein any said substituted C₁-C₆alkyl is substituted by 1 to 3 groups independently selected

15 from the group consisting of unsubstituted C₃-C₇cycloalkyl, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, difluoromethyl, trifluoromethyl, halo, -NR'R'', cyano, hydroxyl, C₁-C₄alkoxy, -COOH, -COO(methyl), -COO(ethyl), and -C(O)NR^cR^d, wherein R' and R'' are each independently selected from the group consisting of hydrogen, unsubstituted C₁-C₆alkyl, -C(O)R^b, and unsubstituted C₃-C₇cycloalkyl, wherein R^b is unsubstituted C₁-C₆alkyl,

20 C₃-C₇cycloalkyl, or heterocyclyl;

and wherein each R^c and R^d are independently hydrogen or C₁-C₆alkyl;

n is 0-2;

or a pharmaceutically acceptable salt thereof.

25 3. A compound of claim 2, wherein A is a 5-membered heterocyclic ring, which may contain 1 or 2 double bonds and may be substituted by 1 to 3 groups independently selected from the group consisting of C₁-C₆alkyl, substituted C₁-C₆alkyl, C₃-C₇cycloalkyl,

halo, hydroxyl, oxo, $-\text{C}(\text{O})\text{NR}^{\text{c}}\text{R}^{\text{d}}$, $-\text{COOH}$, $-\text{C}(\text{O})\text{R}_{\text{a}}$, $-\text{SO}_2\text{R}_{\text{a}}$, arylalkyl, $-(\text{C}_1\text{-C}_3\text{alkyl})\text{aryloxy}$, aryl, heteroaryl and $\text{C}_1\text{-C}_4\text{alkoxy}$,

in which each R_{a} is independently $\text{C}_1\text{-C}_6\text{alkyl}$, substituted $\text{C}_1\text{-C}_6\text{alkyl}$ or unsubstituted $\text{C}_3\text{-C}_7\text{cycloalkyl}$;

- 5 wherein any said substituted $\text{C}_1\text{-C}_6\text{alkyl}$ is substituted by 1 to 3 groups independently selected from the group consisting of unsubstituted $\text{C}_3\text{-C}_7\text{cycloalkyl}$, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, difluoromethyl, trifluoromethyl, halo, $-\text{NR}'\text{R}''$, cyano, hydroxyl, $\text{C}_1\text{-C}_4\text{alkoxy}$, $-\text{COOH}$, $-\text{COO}(\text{methyl})$, $-\text{COO}(\text{ethyl})$, and $-\text{C}(\text{O})\text{NR}^{\text{c}}\text{R}^{\text{d}}$, wherein R' and R'' are each independently selected from the group consisting of hydrogen, unsubstituted $\text{C}_1\text{-C}_6\text{alkyl}$, $-\text{C}(\text{O})\text{R}^{\text{b}}$, and unsubstituted $\text{C}_3\text{-C}_7\text{cycloalkyl}$, wherein R^{b} is unsubstituted $\text{C}_1\text{-C}_6\text{alkyl}$, $\text{C}_3\text{-C}_7\text{cycloalkyl}$, or heterocyclyl;
- 10 and wherein each R^{c} and R^{d} are independently hydrogen or $\text{C}_1\text{-C}_6\text{alkyl}$;;
or a pharmaceutically acceptable salt thereof.

- 15 4. A compound of claim 2, wherein A is a 6-membered heterocyclic ring, which may contain 1 to 3 double bonds and may be substituted by 1 to 3 groups selected from the group consisting of $\text{C}_1\text{-C}_6\text{alkyl}$, substituted $\text{C}_1\text{-C}_6\text{alkyl}$, $\text{C}_3\text{-C}_7\text{cycloalkyl}$, halo, hydroxyl, oxo, $-\text{C}(\text{O})\text{NR}^{\text{c}}\text{R}^{\text{d}}$, $-\text{COOH}$, $-\text{C}(\text{O})\text{R}_{\text{a}}$, $-\text{SO}_2\text{R}_{\text{a}}$, arylalkyl, $-(\text{C}_1\text{-C}_3\text{alkyl})\text{aryloxy}$, aryl, heteroaryl and $\text{C}_1\text{-C}_4\text{alkoxy}$,

- 20 in which each R_{a} is independently $\text{C}_1\text{-C}_6\text{alkyl}$, substituted $\text{C}_1\text{-C}_6\text{alkyl}$ or unsubstituted $\text{C}_3\text{-C}_7\text{cycloalkyl}$;

- wherein any said substituted $\text{C}_1\text{-C}_6\text{alkyl}$ is substituted by 1 to 3 groups independently selected from the group consisting of unsubstituted $\text{C}_3\text{-C}_7\text{cycloalkyl}$, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, difluoromethyl, trifluoromethyl, halo, $-\text{NR}'\text{R}''$, cyano, hydroxyl, $\text{C}_1\text{-C}_4\text{alkoxy}$, $-\text{COOH}$, $-\text{COO}(\text{methyl})$, $-\text{COO}(\text{ethyl})$, and $-\text{C}(\text{O})\text{NR}^{\text{c}}\text{R}^{\text{d}}$, wherein R' and R'' are each independently selected from the group consisting of hydrogen, unsubstituted $\text{C}_1\text{-C}_6\text{alkyl}$, $-\text{C}(\text{O})\text{R}^{\text{b}}$, and unsubstituted $\text{C}_3\text{-C}_7\text{cycloalkyl}$, wherein R^{b} is unsubstituted $\text{C}_1\text{-C}_6\text{alkyl}$, $\text{C}_3\text{-C}_7\text{cycloalkyl}$, or heterocyclyl;
- 25 and wherein each R^{c} and R^{d} are independently hydrogen or $\text{C}_1\text{-C}_6\text{alkyl}$;
- 30 or a pharmaceutically acceptable salt thereof.

5. A compound of any one of claims 2-4, wherein n is 0 and X is N, or a pharmaceutically acceptable salt thereof.

6. A compound of any one of claims 2-4, wherein n is 0 and X is CH, or a pharmaceutically acceptable salt thereof.
- 5 7. A compound of claim 1, wherein:
 R_1 is a bicyclic ring system selected from the group consisting of tetrahydroisoquinoliny, tetrahydroquinoliny, indolyl, dihydroindolyl, indazolyl, dihydroindazolyl, benzothiophenyl, benzodiazolyl, dihydrobenzodiazolyl, benzimidazolyl, indoliny, benzotriazolyl, pyrrolopyridiny, benzothiazolyl, benzofuranyl, dihydroquinazoliny, and pyrrolopyrimidiny;
 10 wherein said bicyclic ring system may be substituted by 1 to 3 groups independently selected from the group consisting of C_1 - C_6 alkyl, substituted C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, halo, hydroxyl, oxo, $-C(O)NR^cR^d$, $-COOH$, $-C(O)R_a$, $-SO_2R_a$, arylalkyl, $-(C_1-C_3alkyl)aryloxy$, aryl, heteroaryl and C_1 - C_4 alkoxy,
 in which each R_a is independently C_1 - C_6 alkyl, substituted C_1 - C_6 alkyl or unsubstituted C_3 -
 15 C_7 cycloalkyl;
 wherein any said substituted C_1 - C_6 alkyl is substituted by 1 to 3 groups independently selected from the group consisting of unsubstituted C_3 - C_7 cycloalkyl, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, difluoromethyl, trifluoromethyl, halo, $-NR'R''$, cyano, hydroxyl, C_1 - C_4 alkoxy, $-COOH$, $-COO(methyl)$, $-COO(ethyl)$, and $-C(O)NR^cR^d$, wherein R' and R'' are
 20 each independently selected from the group consisting of hydrogen, unsubstituted C_1 - C_6 alkyl, $-C(O)R^b$, and unsubstituted C_3 - C_7 cycloalkyl, wherein R^b is unsubstituted C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, or heterocyclyl;
 and wherein each R^c and R^d are independently hydrogen or C_1 - C_6 alkyl;
 or a pharmaceutically acceptable salt thereof.
- 25 8. A compound of claim 7, wherein:
 R_1 is a bicyclic ring system selected from the group consisting of tetrahydroisoquinoliny, tetrahydroquinoliny, indolyl, dihydroindolyl, indazolyl, dihydroindazolyl, and pyrrolopyridiny;
 30 wherein said bicyclic ring system may be substituted by 1 to 3 groups selected from the group consisting of C_1 - C_6 alkyl, substituted C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, halo, hydroxyl, oxo, $-C(O)NR^cR^d$, $-COOH$, $-C(O)R_a$, $-SO_2R_a$, arylalkyl, $-(C_1-C_3alkyl)aryloxy$, aryl, heteroaryl and C_1 - C_4 alkoxy,

in which each R_a is independently C₁-C₆alkyl, substituted C₁-C₆alkyl or unsubstituted C₃-C₇cycloalkyl;

- wherein any said substituted C₁-C₆alkyl is substituted by 1 to 3 groups independently selected from the group consisting of unsubstituted C₃-C₇cycloalkyl, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, difluoromethyl, trifluoromethyl, halo, -NR'R'', cyano, hydroxyl, C₁-C₄alkoxy, -COOH, -COO(methyl), -COO(ethyl), and -C(O)NR^cR^d, wherein R' and R'' are each independently selected from the group consisting of hydrogen, unsubstituted C₁-C₆alkyl, -C(O)R^b, and unsubstituted C₃-C₇cycloalkyl, wherein R^b is unsubstituted C₁-C₆alkyl, C₃-C₇cycloalkyl, or heterocyclyl;
- 10 and wherein each R^c and R^d are independently hydrogen or C₁-C₆alkyl; or a pharmaceutically acceptable salt thereof.

9. The compound according to claim 1, selected from the group consisting of:
- 2-(6-{4-amino-5-oxo-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-6-yl}-1-oxo-1,2,3,4-tetrahydroisoquinolin-2-yl)acetic acid;
- 15 ethyl 2-(6-{4-amino-5-oxo-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-6-yl}-2-oxo-1,2,3,4-tetrahydroquinolin-1-yl)acetate;
- 2-(6-{4-amino-5-oxo-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-6-yl}-2-oxo-1,2,3,4-tetrahydroquinolin-1-yl)acetic acid;
- 20 ethyl 2-(6-{4-amino-5-oxo-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-6-yl}-1-oxo-1,2,3,4-tetrahydroisoquinolin-2-yl)acetate;
- 6-{4-amino-5-oxo-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-6-yl}-1-methyl-1,2,3,4-tetrahydroquinolin-2-one;
- 6-{4-amino-5-oxo-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-6-yl}-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-one;
- 25 6-{4-amino-5-oxo-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-6-yl}-2-benzyl-1,2,3,4-tetrahydroisoquinolin-1-one;
- 6-{4-amino-5-oxo-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-6-yl}-2-propyl-1,2,3,4-tetrahydroisoquinolin-1-one;
- 30 6-{4-amino-5-oxo-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-6-yl}-1-propyl-1,2,3,4-tetrahydroquinolin-2-one;
- 5-{4-amino-5-oxo-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-6-yl}-2-benzyl-1-(prop-2-en-1-yl)-2,3-dihydro-1H-indazol-3-one;

- 5-{4-amino-5-oxo-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-6-yl}-1-propyl-2,3-dihydro-1H-indazol-3-one;
- 4-amino-6-(1-propyl-1H-indol-5-yl)-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-(1-propyl-1H-indazol-5-yl)-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 5 4-amino-6-(1-benzothiophen-5-yl)-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 5-{4-amino-5-oxo-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-6-yl}-1,3-dipropyl-2,3-dihydro-1H-1,3-benzodiazol-2-one;
- 4-amino-6-(2-propyl-2H-indazol-5-yl)-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-(1,3-benzothiazol-6-yl)-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 10 5-{4-amino-5-oxo-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-6-yl}-1-propyl-2,3-dihydro-1H-indole-2,3-dione;
- 4-amino-6-(1-benzofuran-5-yl)-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-(1-cyclopropyl-1,2,3,4-tetrahydroquinolin-6-yl)-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 15 4-amino-6-(2-propyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-[1-(2,2-difluoroethyl)-1,2,3,4-tetrahydroquinolin-6-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 5-{4-amino-5-oxo-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-6-yl}-1-(propan-2-yl)-2,3-dihydro-1H-indazol-3-one;
- 20 5-{4-amino-5-oxo-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-6-yl}-1-(2-methoxyethyl)-2,3-dihydro-1H-indazol-3-one;
- 5-{4-amino-5-oxo-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-6-yl}-1-(2,2-difluoroethyl)-2,3-dihydro-1H-indazol-3-one;
- 25 5-{4-amino-5-oxo-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-6-yl}-1-cyclopropyl-2,3-dihydro-1H-indazol-3-one;
- 6-amino-4-(1-propyl-1H-1,3-benzodiazol-5-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-5-one;
- 4-amino-6-(1-propyl-1H-1,3-benzodiazol-6-yl)-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 30 4-amino-6-(2-propyl-2H-1,2,3-benzotriazol-5-yl)-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-(1-propyl-1H-1,2,3-benzotriazol-6-yl)-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;

- 4-amino-6-(2-methyl-1,3-benzothiazol-5-yl)-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-[1-(2,2-difluoroethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 5 4-amino-6-{1-(cyclopropyl)-1H-pyrrolo[2,3-b]pyridin-5-yl}-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-[1-(cyclopropylmethyl)-1H-indol-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 3-(5-{4-amino-5-oxo-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-6-yl}-1H-indol-1-yl)propanoic acid;
- 10 4-amino-6-[1-(cyclohexylmethyl)-1H-indol-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-[1-(pentan-3-yl)-1H-indol-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 15 4-amino-6-{1-[(4-methoxyphenyl)methyl]-1H-indol-5-yl}-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-{1-[(4-fluorophenyl)methyl]-1H-indol-5-yl}-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-{1-[2-(benzyloxy)ethyl]-1H-indol-5-yl}-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 20 4-amino-6-(1-benzyl-1H-indol-5-yl)-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-[1-(3-methoxypropyl)-1H-indol-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-[1-(2,2-difluoroethyl)-1H-indol-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 25 4-amino-6-(1-methyl-1H-indol-5-yl)-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-[1-(2-methoxyethyl)-1H-indol-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-[1-(propan-2-yl)-1H-indol-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 30 4-amino-6-(1H-indol-5-yl)-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-(1-propyl-2,3-dihydro-1H-indol-5-yl)-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;

- 4-amino-6-(2,3-dihydro-1H-indol-5-yl)-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
 4-amino-6-[1-(2-methoxyethyl)-2,3-dihydro-1H-indol-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
 4-amino-6-(1,2-dimethyl-1H-indol-5-yl)-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
 5 4-amino-6-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
 4-amino-6-{1-propyl-1H-pyrrolo[2,3-b]pyridin-5-yl}-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
 4-amino-6-[1-(2-methoxyethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
 10 f][1,4]oxazepin-5-one;
 4-amino-6-[1-(cyclohexylmethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
 4-amino-6-{1-cyclohexyl-1H-pyrrolo[2,3-b]pyridin-5-yl}-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
 15 4-amino-6-[1-(propan-2-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
 4-amino-6-[1-(2-hydroxyethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
 4-amino-6-(1-methanesulfonyl-1H-indol-5-yl)-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
 20 one;
 4-amino-6-(1-cyclopropyl-1H-indol-5-yl)-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
 5-{4-amino-5-oxo-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-6-yl}-1-propyl-1H-indole-2-carboxylic acid;
 4-amino-6-[1-propyl-3-(trifluoroacetyl)-1H-indol-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
 25 f][1,4]oxazepin-5-one;
 4-amino-6-[1-propyl-3-(1,1,1-trifluoro-2-methoxypropan-2-yl)-1H-indol-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
 4-amino-6-(1-phenyl-1H-indol-5-yl)-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
 4-amino-6-{1-[4-(trifluoromethyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
 30 pyrimido[5,4-f][1,4]oxazepin-5-one;
 4-amino-6-[1-(4-fluorophenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;

- 4-amino-6-[1-(3-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-[1-(3-chlorophenyl)-1H-indol-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 5 4-amino-6-[1-(2-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-[1-(2-methoxyphenyl)-1H-indol-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-{1-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl}-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 10 4-amino-6-[1-(2-fluorophenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-[1-(3,4-difluorophenyl)-1H-indol-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 15 4-amino-6-[1-(3,4-difluorophenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-[1-(2-fluorophenyl)-1H-indol-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-{1-[4-(trifluoromethyl)phenyl]-1H-indol-5-yl}-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 20 4-amino-6-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-{1-[3-(trifluoromethyl)phenyl]-1H-indol-5-yl}-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 25 4-amino-6-{1-[3-(trifluoromethyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-[1-(1,3-thiazol-2-yl)-1H-indol-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-{1-[6-(trifluoromethyl)pyridin-3-yl]-1H-indol-5-yl}-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 30 4-amino-6-[1-(pyridin-2-yl)-1H-indol-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;

- 4-amino-6-[1-(pyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-[1-(pyrazin-2-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 5 4-amino-6-[1-(pyrazin-2-yl)-1H-indol-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-{1-[5-(trifluoromethyl)pyridin-2-yl]-1H-indol-5-yl}-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-{1-[5-(trifluoromethyl)pyridin-2-yl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-
- 10 5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-[1-(1,3-thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-{1-[6-(trifluoromethyl)pyridin-3-yl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-
- 5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 15 4-amino-6-[1-phenyl-3-(propan-2-yl)-1H-indol-5-yl]-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-(2-phenyl-1-propyl-1H-indol-5-yl)-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-(6-fluoro-1-phenyl-1H-indol-5-yl)-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-
- 20 one;
- 6-{4-amino-5-oxo-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-6-yl}-3-benzyl-3,4-dihydroquinazolin-4-one;
- 6-{4-amino-5-oxo-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-6-yl}-3,4-dihydroquinazolin-4-one;
- 25 4-amino-6-(1-benzyl-6-fluoro-1H-indol-5-yl)-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-{5-propyl-5H-pyrrolo[3,2-d]pyrimidin-2-yl}-5H,6H,7H,8H-pyrimido[5,4-f][1,4]oxazepin-5-one;
- 4-amino-6-(1-propyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-7,8-dihydropyrimido[5,4-
- 30 f][1,4]oxazepin-5(6H)-one;
- 4-amino-6-(1-(6-methylpyridin-3-yl)-1H-indol-5-yl)-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one;

- 4-amino-6-(1-(4-(difluoromethyl)phenyl)-1H-indol-5-yl)-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one;
- 4-amino-6-(1-(4-(difluoromethyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one; and
- 5 4-amino-6-(1-(4-(trifluoromethyl)pyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one;
- or a pharmaceutically acceptable salt thereof.
10. Use of the compound or salt according to any one of claims 1-9 in the manufacture
- 10 of a medicament for the treatment of obesity.
11. A pharmaceutical composition comprising the compound or salt according to any one of claims 1-9, and a pharmaceutically acceptable carrier.